Tomomitsu Hotta

Nagoya Medical Center — Japan

Medicine · Health Sciences

44h-index9.2kcitations241works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(66), Hematopoietic Stem Cell Transplantation(37), Chronic Lymphocytic Leukemia Research(34), Viral-associated cancers and disorders(27), Immune Cell Function and Interaction(25)

Publications240 total

Final results of JCOG0601 randomized trial of R-CHOP versus CHOP combined with dose-dense rituximab for diffuse large B-cell lymphoma
Japanese Journal of Clinical Oncology·2025
Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy – a supplementary analysis of JCOG0601
Annals of Hematology·2024· 2 citedOpen Access
Final Analysis of the Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab for DLBCL: JCOG0601
Blood·2023Open Access
Long‐term follow‐up after <scp>R‐High CHOP</scp>/<scp>CHASER</scp>/<scp>LEED</scp> with <scp>Auto‐PBSCT</scp> in untreated mantle cell lymphoma—Final analysis of <scp>JCOG0406</scp>
Cancer Science·2023· 1 citedOpen Access
Prediction of tissue-of-origin of early stage cancers using serum miRNomes
JNCI Cancer Spectrum·2022· 31 citedOpen Access
A multicenter, phase II study of full-dose THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, aggressive non-Hodgkin lymphoma
Journal of Clinical and Experimental Hematopathology·2022· 2 citedOpen Access
A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial
Blood Advances·2021· 34 citedOpen Access
A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphoma
Journal of Clinical and Experimental Hematopathology·2021Open Access
Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study – JCOG0108A
Journal of Clinical and Experimental Hematopathology·2021· 1 citedOpen Access
R‐CHOP‐14 versus R‐CHOP‐14/CHASER for upfront autologous transplantation in diffuse large B‐cell lymphoma: JCOG0908 study
Cancer Science·2020· 3 citedOpen Access
Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601
Blood·2018
Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial
The Lancet Haematology·2018· 22 cited
Brief history of the Asiatic International Society of Hematology: our roots of international cooperation with Asian countries
International Journal of Hematology·2018
R‐High‐<scp>CHOP</scp>/<scp>CHASER</scp>/<scp>LEED</scp> with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY
Cancer Science·2018· 18 citedOpen Access
A Phase II Study of THP-COP (pirarubicin, cyclophosphamide, vincristine and prednisolone) in Patients with Newly Diagnosed Advanced Peripheral T-Cell Lymphoma: THP-3 Study of Japan Hematopoietic Malignancy Clinical Study Group (HMCSG)
Blood·2017· 1 cited
Present Status and Future Perspectives of Cancer Practice in Elderly
Health Evaluation and Promotion·2017· 6 citedOpen Access
A randomized, double‐blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during <scp>CHASE</scp>(R) chemotherapy for malignant lymphoma
British Journal of Haematology·2016· 44 citedOpen Access
Long-term follow-up results of a phase I/II study of melphalan, prednisolone and bortezomib in Japanese transplant-ineligible multiple myeloma patients (JPN-102).
PubMed·2016
A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma
International Journal of Hematology·2015· 15 cited
The Nationwide Cancer Genome Screening Projects for Gastrointestinal Cancer in Japan (SCRUM-Japan GI-SCREEN): Efficient identification of actionable cancer genome alterations in advanced colorectal and non-colorectal gastrointestinal cancer (GI Screen 2013-01-CRC and 2015-01-Non CRC).
Journal of Clinical Oncology·2015· 3 cited
page 1 of 12Next →

Frequent Co-authors

Kiyoshi Ando(24), Kensei Tobinai(10), Shunichi Kato(10), Tomohiro Kinoshita(8), Hidehiko Saito(8), Daisuke Sakai(7), Joji Mochida(7), Hiroshi Kawada(6), Kunihiro Tsukasaki(6), Yoshihiko Nakamura(6), Yukio Kobayashi(6), Yukari Muguruma(5), M Shimoyama(5), Toru Iwashina(5), Noriko Usui(5), Takashi Yahata(5), Michinori Ogura(5), Hiroko Miyatake(4), Yasuo Ikeda(4), Masao Tomonaga(4)